UroToday - The Global Online Community of Urologists
Reno, Nevada (UroToday.com) -- Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for …
UroToday
1 天前 · Published 05 November 2024 . PROpel (NCT03732820) was a positive phase 3 trial that demonstrated a clinically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer.
UroToday - The Global Online Community of Urologists
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Highlights in Prostate Cancer Treatment Advances from ESMO …
19 小时之前 · Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide...
The Latest Research on Bladder Cancer - UroToday
Bladder cancer remains the sixth most commonly diagnosed cancer in the United States, with an estimated 82,290 incident cases in 2023. 1 Because of the persistent recurrence risk of NMIBC in a highly comorbid population, there has been an FDA-led drive towards developing novel treatment options for these patients. The following article will highlight recent advances in this disease space with ...
Prostate Cancer - UroToday
2024年9月25日 · Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
The Latest Research on Bladder Health - UroToday
2022年7月5日 · The American Urological Association (AUA) released a guideline update on the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome with 26 updated guideline statements on diagnosis and approach to management.Evidence levels assigned included a strength rating of A (high), B (moderate), or C (low) but many recommendations were based on Clinical Principles and Expert Opinion ...
ASCO GU 2024 Videos - UroToday
UroToday's exclusive Video Lecture coverage of ASCO GU 2024. Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
2024 American Urological Association (AUA) - UroToday
AUA 2024 Prostate Cancer. AUA 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib (AZD5305) in Combination with New Hormonal Agents in Patients with mCSPC +/- HRR Mutations
AUA Guidelines 2020: Microhematuria - UroToday
(UroToday.com) The guidelines for microhematuria were formulated by a multidisciplinary panel with representations from the American Urological Association (AUA), Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), and American College of Obstetricians and Gynecologists (ACOG), as well as Bladder Cancer Advocacy Network (BCAN) patient advocate.